The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
出版年份 2014 全文链接
标题
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
作者
关键词
-
出版物
PHARMACOGENOMICS JOURNAL
Volume 14, Issue 5, Pages 424-431
出版商
Springer Nature
发表日期
2014-04-08
DOI
10.1038/tpj.2014.16
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
- (2012) Mafalda M Dias et al. PHARMACOGENOMICS
- A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
- (2011) E Marcuello et al. BRITISH JOURNAL OF CANCER
- Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients
- (2011) Katerina Shulman et al. CANCER
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial
- (2011) Michel Ducreux et al. LANCET ONCOLOGY
- Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement
- (2011) A. Cecile J. W. Janssens et al. PLOS MEDICINE
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
- (2010) E Martinez-Balibrea et al. BRITISH JOURNAL OF CANCER
- Molecular predictive and prognostic markers in colon cancer
- (2010) Thomas Winder et al. CANCER TREATMENT REVIEWS
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
- (2010) Howard L. McLeod et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia
- (2010) Yoichi Nakamura et al. Journal of Thoracic Oncology
- The UGT1A1*28 Genotype and the Toxicity of Low-Dose Irinotecan in Patients With Advanced Lung Cancer
- (2010) Tomohide Sugiyama et al. ONCOLOGY RESEARCH
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
- (2009) Heather Taffet Gold et al. CANCER
- Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
- (2009) GENETICS IN MEDICINE
- Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
- (2009) Glenn E Palomaki et al. GENETICS IN MEDICINE
- UGT1A and Irinotecan Toxicity: Keeping It in the Family
- (2009) Janelle M. Hoskins et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
- (2009) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
- (2009) Giuseppe Toffoli et al. JOURNAL OF CLINICAL ONCOLOGY
- UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
- (2009) Christoph Schulz et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The Millennium Development Goals Fail Poor Children: The Case for Equity-Adjusted Measures
- (2009) Daniel D. Reidpath et al. PLOS MEDICINE
- STrengthening the REporting of Genetic Association Studies (STREGA)— An Extension of the STROBE Statement
- (2009) Julian Little et al. PLOS MEDICINE
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
- UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
- (2008) Chun-Yu Liu et al. CANCER
- Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics
- (2008) John F. Deeken et al. CANCER
- Systematic Review and Meta-analysis: When One Study Is Just not Enough
- (2008) A. X. Garg et al. Clinical Journal of the American Society of Nephrology
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost–effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
- (2008) Marko Obradovic et al. PHARMACOGENOMICS
- Methodological quality of pharmacogenetic studies: Issues of concern
- (2008) Andrea L. Jorgensen et al. STATISTICS IN MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started